摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

t-butyl 4-((6-chloropyridazine-3-yloxy)methyl)piperidin-1-carboxylate | 1010072-64-6

中文名称
——
中文别名
——
英文名称
t-butyl 4-((6-chloropyridazine-3-yloxy)methyl)piperidin-1-carboxylate
英文别名
tert-butyl 4-{[(6-chloropyridazin-3-yl)oxy]methyl}piperidine-1-carboxylate;1,1-dimethylethyl 4-{[(6-chloro-3-pyridazinyl)oxy]methyl}-1-piperidinecarboxylate;tert-butyl 4-[(6-chloropyridazin-3-yl)oxymethyl]piperidine-1-carboxylate
t-butyl 4-((6-chloropyridazine-3-yloxy)methyl)piperidin-1-carboxylate化学式
CAS
1010072-64-6
化学式
C15H22ClN3O3
mdl
——
分子量
327.811
InChiKey
XLGZWOOEWNQLJE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    22
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    64.6
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS
    申请人:Fang Jing
    公开号:US20100029650A1
    公开(公告)日:2010-02-04
    The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
    本发明涉及一种新型化合物,该化合物在治疗代谢性疾病,特别是Ⅱ型糖尿病及相关疾病方面具有用途,并且还涉及制备和使用这种化合物的方法。
  • [EN] PIPERIDINE DERIVATIVES FOR GPR119 AGONIST<br/>[FR] DÉRIVÉS DE PIPÉRIDINE AGONISTES DE GPR119
    申请人:CHONG KUN DANG PHARM CORP
    公开号:WO2013187646A1
    公开(公告)日:2013-12-19
    The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.
    本发明涉及新型哌啶衍生物,其立体异构体或其药学上可接受的盐;制备该化合物的方法;以及包含该化合物的药物组合物。根据本发明,具有GPR119激动剂作用的新型哌啶衍生物可用于治疗代谢性疾病,包括糖尿病(特别是II型)及相关疾病。
  • New compounds
    申请人:Brandt Peter
    公开号:US20080058339A1
    公开(公告)日:2008-03-06
    The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers and N-oxides thereof. The invention also relates to pharmaceutical compositions comprising these compounds, and to the use of these compounds for the prophylaxis and treatment of medical conditions relating to disorders of the G-protein-coupled receptor GPR119, such as diabetes and obesity.
    本发明涉及公式(I)的化合物及其药学上可接受的盐、水合物、几何异构体、外消旋体、互变异构体、光学异构体和N-氧化物。本发明还涉及包含这些化合物的药物组合物,以及使用这些化合物预防和治疗与G蛋白偶联受体GPR119相关的医学疾病,如糖尿病和肥胖症。
  • Bicyclic compounds and use as antidiabetics
    申请人:GlaxoSmithKline LLC
    公开号:US08101634B2
    公开(公告)日:2012-01-24
    The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
    本发明涉及一种新型化合物,可用于治疗代谢性疾病,特别是II型糖尿病及相关疾病,并且还涉及制备和使用这种化合物的方法。
  • Antagonists of the muscarinic acetylcholine receptor M4
    申请人:Vanderbilt University
    公开号:US11325896B2
    公开(公告)日:2022-05-10
    Disclosed herein are substituted 2-azaspiro[3.3]heptane compounds of formula (I′), which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    本文公开了式(I′)的取代的2-氮杂螺[3.3]庚烷化合物,它们可用作毒蕈碱乙酰胆碱受体M4(mAChR M4)的拮抗剂。本文还公开了制造这些化合物的方法、包含这些化合物的药物组合物以及使用这些化合物和组合物治疗疾病的方法。
查看更多